Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1429-1439

  Stiles, Brendon M ^a   Adusumilli, Prasad S ^a   Stanziale, Stephen F ^a   Eisenberg, David P ^a   Bhargava, Amit ^a   Kim, Teresa H ^a   Chan, Mei Ki ^a   Huq, Rumana ^a   Gonen, Mithat ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Herpes simplex; Hormonal therapy; Replication competent viruses

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR;

ARTICLE; BREAST TUMOR; CELL DIVISION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; MUTATION; PATHOLOGY; TUMOR CELL LINE; VIRUS REPLICATION;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ESTROGENS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; HUMANS; MUTATION; RECEPTORS, ESTROGEN; VIRUS REPLICATION;

EID: 33747107517     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1429     Document Type: Article

References (49)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Lippert TH, Seeger H and Mueck AO: The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 65: 357-369, 2000.
3. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A and Bhalla K: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42: 73-81, 1997.
4. Razandi M, Pedram A and Levin ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 14: 1434-1447, 2000.
5. Swiatecka J, Dzieciol J, Anchim T, Dabrowska M, Pietruczuk M and Wolczynski S: Influence of estrogen, antiestrogen and UV-light on the balance between proliferation and apoptosis in MCF-7 breast adenocarcinoma cells culture. Neoplasma 47: 15-24, 2000.
6. Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
7. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998.
8. Toda M, Rabkin SD and Martuza RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9: 2177-2185, 1998.
9. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD and Martuza RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10: 2237-2243, 1999.
10. Mineta T, Rabkin SD, Yazaki T, Hunter WD and Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943, 1995.
11. Ebright MI, Zager JS, Malhotra S, Delman KA, Weigel TL, Rusch VW and Fong Y: Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 124: 123-129, 2002.
12. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ and Fong Y: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 13: 1325-1334, 1999.
13. Carew JF, Kooby DA, Halterman MW, Federoff HJ and Fong Y: Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10: 1599-1606, 1999.
14. Galvan V and Roizman B: Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA 95: 3931-3936, 1998.
15. Roizman B: The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 93: 11307-11312, 1996.
16. Galvan V, Brandimarti R, Munger J and Roizman B: Bcl-2 blocks a caspase-dependent pathway of apoptosis activated by herpes simplex virus 1 infection in HEp-2 cells. J Virol 74: 1931-1938, 2000.
17. Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR and Rabkin SD: Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res 6: 3009-3015, 2001.
18. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B and Fong Y: Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 13: 1213-1223, 2002.
19. Leopardi R and Roizman B: The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA 93: 9583-9587, 1996.
20. He B, Gross M and Roizman B: The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843-848, 1997.
21. Darzynkiewicz Z and Traganos F: Measurement of apoptosis. Adv Biochem Eng Biotechnol 62: 33-73, 1998.
22. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
23. Whitley RJ and Roizman B: Herpes simplex viruses: is a vaccine tenable? J Clin Invest 110: 145-151, 2002.
24. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F and Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874, 2000.
25. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, Maclean A, Harland J, McKie E, Mabbs R and Brown M: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866, 2000.
26. Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, Donahue JM, Chiocca EA, Chung RY and Tanabe KK: Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 109: 871-882, 2002. (Pubitemid 34275108)
27. Bennett JJ and Fong Y: Viral-based therapies for liver cancer. HPB 2: 289-298, 2000.
28. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G and Cetto GL: Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74: 433-437, 1997.
29. Gerdes J, Pickartz H, Brotherton J, Hammerstein J, Weitzel H and Stein H: Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol 129: 486-492, 1987.
30. Somlo G, Simpson JF, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Raschko J, Shibata S, Forman S, Kogut N, McNamara M, Molina A, Somlo E amd Doroshow JH: Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 87: 281-288, 2002.
31. Dickson RB and Stancel GM: The Bcl-2 protein family: arbiters of cell survival. J Natl Cancer Inst Monogr 27: 135-145, 2000.
32. Warri AM, Huovinen RL, Laine AM, Martikainen PM and Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993.
33. Kyprianou N, English HF, Davidson NE and Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166, 1991.
34. Diel P, Smolnikar K and Michna H: The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87-97, 1999.
35. Wilson JW, Wakeling AE, Morris ID, Hickman JA and Dive C: MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int J Cancer 61: 502-508, 1995.
36. Koyama AH and Miwa Y: Suppression of apoptotic DNA fragmentation in herpes simplex virus type 1-infected cells. J Virol 71: 2567-2571, 1997.
37. Zachos G, Koffa M, Preston CM, Clements JB and Conner J: Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication. J Virol 75: 2710-2728, 2001.
38. Fernandez Y, Gu B, Martinez A, Torregrosa A and Sierra A: Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer 101: 317-326, 2002.
39. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW and Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
40. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F and Piubello Q: bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4: 2331-2336, 1998.
41. Stanziale SF, Petrowsky H, Adusumilli PS, Ben Porat L, Gonen M and Fong Y: Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 10: 3225-3232, 2004.
42. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA and Zangemeister-Wittke U: Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 76: 157-166, 2002.
43. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV and McCubrey JA: Raf-1 and bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9: 1161-1177, 2003.
44. Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH and Mayer LD: Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 63: 199-212, 2000.
45. Johnston SR: Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 810: 911-930, 1997.
46. Osborne CK, Yochmowitz MG, Knight WA III and McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (suppl 12): 2884-2888, 1980.
47. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK and Benz CC: Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res 57: 3723-3727, 1997.
48. Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, Zager JS, Chou TC and Fong Y: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 18: 1001-1003, 2004.
49. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben Porat L, Gonen M and Fong YM: Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132: 353-359, 2002.